Indivior PLC has announced its intention to cancel the secondary listing of its Ordinary Shares on the London Stock Exchange. The company will maintain its primary listing on the Nasdaq. The Board believes the London delisting will be beneficial for several reasons.
It fully aligns with Indivior’s strategic focus on the U.S. market, where over 80% of its net revenue is generated. It eliminates the cost and complexity of maintaining a secondary listing. It also acknowledges that liquidity on Nasdaq now represents approximately 75% of total trading volume across both exchanges over the last 30 days.
David Wheadon, Chair of Indivior, said: “We are pleased to announce this key milestone for Indivior following our evaluation period. A single primary listing on Nasdaq best reflects the profile of Indivior’s business.
indivior’s London delisting announcement
We appreciate the support received from shareholders for this initiative and look forward to capitalizing on the expected benefits of this move, including reductions in cost and complexity.”
Indivior is providing approximately 40 business days’ notice, with the London delisting intended to become effective on July 25, 2025. Consequently, the last day of trading on the LSE will be July 24, 2025. After the London delisting, it will no longer be possible to trade Ordinary Shares on the LSE.
The listing on Nasdaq will be maintained. The London delisting is expected to have no impact on shareholders who are direct holders of Ordinary Shares or those holding interests through their nominated DTC broker or custodian. Holders of U.K. issued Indivior Depositary Interests (U.K. DIs) and participants in Indivior’s Corporate Sponsored Nominee facility (CSN) are encouraged to read Appendix 1 of the announcement for further details.
The Takeover Code will continue to apply to Indivior for two years after the London delisting. As per the Code, a mandatory cash offer will be required if any person acquires an interest in Ordinary Shares that, together with shares already held, grants them 30% or more of the voting rights of the Company. Indivior is a global pharmaceutical company dedicated to developing medicines to treat opioid use disorder and other conditions, helping to change patients’ lives.